ASSAYS, METHODS AND KITS FOR MEASURING RESPONSE TO THERAPY AND PREDICTING CLINICAL OUTCOME IN PATIENTS WITH B-CELL LYMPHOMA

摘要

Assays, methods and kits for predicting survival outcome in a subject having diffuse large B-cell lymphoma (DLBCL) and for measuring a subject's response to DLBCL therapy involve specific miRNAs that are prognostic biomarkers for prediction of outcome of DLBCL patients. Expression of miRNAs miR-18a, miR-181a and miR-222 is associated with response to therapy and outcome of patients with DLBCL. Measurement of these miRs can be used to identify patients' outcomes in the clinic and allow tailoring of patient-specific therapy.